Intracerebral hemorrhage drug pipeline

Upcoming readouts & recent results

• Mid-2024DelayedCN-105Topline datapendingNCT06255977

  CN-CATCH, the 240-patient Chinese dose-finding Phase 2, listed an estimated primary completion of May 2024 but has produced no results and its registry record has not been updated since February 2024. ↗

• 2026-06-23ReportedCN-105Full resultsmissedNCT03711903

  S-CATCH: the randomized Phase 2b in 60 Singaporean ICH patients confirmed safety but missed on 90-day functional outcome (mRS <=3 77.8% vs 66.7%, p=0.35). ↗

• 2022-02-01ReportedCN-105Full resultsmetNCT03168581

  CATCH: the open-label Phase 2a in 38 ICH patients met its safety primary with no excess hematoma expansion, and showed a 30-day mRS odds ratio of 2.69 (1.31-5.51) against matched historical controls. ↗

• 2017-06-01ReportedCN-105Full resultsmetNCT02670824

  Phase 1 in 48 healthy adults: no significant safety issues on single or repeated IV dosing, linear PK with ~3.6 h half-life and no accumulation. ↗

See the full catalyst calendar →

Compounds in development (1)

Trials recruiting now

4 registered interventional intracerebral hemorrhage trials — none recruiting at present. Browse all on ClinicalTrials.gov →